UBX Unity Biotechnology Inc.

3.84
+0.18  (+5%)
Previous Close 3.66
Open 3.69
52 Week Low 2.72
52 Week High 15.44
Market Cap $199,833,669
Shares 52,040,018
Float 35,531,516
Enterprise Value $107,700,465
Volume 2,349,655
Av. Daily Volume 1,910,397
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
UBX0101
Osteoarthritis of the knee
Phase 1b
Phase 1b
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
UBX1325
Diabetic macular edema / Age-related macular degeneration
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
UBX0101
Osteoarthritis of the knee
Phase 2
Phase 2
Phase 2 top-line data failed to meet primary endpoint - August 17, 2020.

Latest News

  1. - Corporate restructuring to extend cash runway through mid-2022 and key milestones -

    - UBX1325 to enter clinical development in patients with diabetic macular edema -

    SAN FRANCISCO, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it has initiated a restructuring to align its resources on cellular senescence programs in ophthalmology and neurology while further extending operating capital. UNITY will advance UBX1325 to Phase 1 clinical development in patients with diabetic macular edema, and expects to dose the first patient in the second half of 2020, consistent with…

    - Corporate restructuring to extend cash runway through mid-2022 and key milestones -

    - UBX1325 to enter clinical development in patients with diabetic macular edema -

    SAN FRANCISCO, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it has initiated a restructuring to align its resources on cellular senescence programs in ophthalmology and neurology while further extending operating capital. UNITY will advance UBX1325 to Phase 1 clinical development in patients with diabetic macular edema, and expects to dose the first patient in the second half of 2020, consistent with prior guidance.

    UNITY has prioritized its portfolio and aligned resources to deliver on key development milestones and drive innovation:

    • UBX1325 targets Bcl-xL, a novel mechanism to eliminate senescent cells in age-related diseases of the eye. The UBX1325 Phase 1 study in diabetic macular edema is expected to begin before the end of the year. UBX1967 remains in the portfolio as a molecularly distinct backup to UBX1325. 
    • UNITY's neurology programs will target core features of neurodegenerative diseases. These programs build upon UNITY's foundational cellular senescence research platform and will focus on senolytic therapies for neurological diseases as well as exploring novel mechanisms for cognitive benefit.
    • UNITY's research programs will explore therapeutic modalities beyond small molecule approaches to significantly expand the target space for modulating senescent cell biology implicated as drivers of diseases of aging.

    Revised Financial Guidance

    UNITY will reduce its workforce by approximately 30% to optimize capital allocation and align with key strategic priorities, resulting in an estimated 75 full-time employees by the end of the year. These steps to focus resources are expected to extend the cash runway through mid-2022, with current cash and cash equivalents projected to fund UNITY through key clinical data readouts for UBX1325 and IND-enabling studies for UBX1967.

    "UNITY is a pioneer in the development of therapeutics targeting senescent cells at the crux of many age-related diseases, and we will continue to build on this scientific foundation as we advance our pipeline," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "At UNITY, we have an extraordinary team that has contributed greatly to the advancement of this field, and we are deeply grateful for the contributions that all of our employees have made. Moving forward we will have a leaner and more agile team, which is well-resourced to advance our pipeline programs to key milestones."

    Dr. Ghosh added: "We are excited about advancing UNITY's lead ophthalmology program, UBX1325, into clinical studies in patients with diabetic macular edema, an indication with a well-defined development path and objective endpoints. In addition, I see significant opportunities emerging from programs in our preclinical pipeline targeting ophthalmologic and neurologic disease. I look forward to using my experience leading drug discovery and development programs in these areas to advance the development of a new class of high efficacy therapies."

    About UNITY

    UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.

    Forward-Looking Statements

    This press release contains forward-looking statements including statements related to UNITY's understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to extend healthspan, including for ophthalmologic and neurologic disease, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for diabetic macular edema and other ophthalmological diseases, the expected timing of initial results of the Phase 1 study of UBX1325 in diabetic macular edema, the expected size of UNITY's workforce following the restructuring, the impact of the workforce reduction on UNITY's business, and UNITY's expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITY's most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the Securities and Exchange Commission on July 31, 2020, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

    Investors 
    Endurance Advisors
    Mike Zanoni
      
    
    Media 
    Canale Communications
    Jason Spark
     

    Primary Logo

    View Full Article Hide Full Article
  2. SAN FRANCISCO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the following upcoming September investor conferences:

    Citi 15th Annual BioPharma Virtual Conference
    Date: September 9, 2020
    Location: Virtual – 1x1 only

    Morgan Stanley 18th Annual Global Healthcare Conference
    Date: September 15, 2020
    Fireside Chat Time: 4:15 PM E.T.
    Location: Virtual

    Cantor Fitzgerald Virtual Healthcare Conference Conference
    Date: September 16, 2020
    Presentation Time: 10:00 AM E.T.
    Location: Virtual

    A live audio webcast of the fireside…

    SAN FRANCISCO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the following upcoming September investor conferences:

    Citi 15th Annual BioPharma Virtual Conference

    Date: September 9, 2020

    Location: Virtual – 1x1 only

    Morgan Stanley 18th Annual Global Healthcare Conference

    Date: September 15, 2020

    Fireside Chat Time: 4:15 PM E.T.

    Location: Virtual

    Cantor Fitzgerald Virtual Healthcare Conference Conference

    Date: September 16, 2020

    Presentation Time: 10:00 AM E.T.

    Location: Virtual

    A live audio webcast of the fireside chat and presentation from the Morgan Stanley and Cantor Fitzgerald conferences will be available through the Investors & Media section of UNITY's website. An archived replay will be available for 90 days following each event.

    About UNITY

    UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's initial focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related diseases, such as osteoarthritis, eye diseases, neurological diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.

    Investors 
    Endurance Advisors
    Mike Zanoni
      
    
    Media 
    Canale Communications
    Jason Spark
    

    Primary Logo

    View Full Article Hide Full Article
  3. SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced the appointment of Lynne Sullivan to the permanent role of chief financial officer, effective September 1, 2020.

    "Lynne is an incredibly talented senior finance executive with deep biotech and pharmaceutical industry experience and has already played an impactful role at UNITY over the past several months as she became interim CFO," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "Lynne's experience across corporate finance and business development functions will be key to UNITY's future success. Having…

    SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced the appointment of Lynne Sullivan to the permanent role of chief financial officer, effective September 1, 2020.

    "Lynne is an incredibly talented senior finance executive with deep biotech and pharmaceutical industry experience and has already played an impactful role at UNITY over the past several months as she became interim CFO," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "Lynne's experience across corporate finance and business development functions will be key to UNITY's future success. Having worked with Lynne previously, I know that she will be an outstanding member of our executive team as we redouble our efforts to develop a new class of therapeutics to slow, halt or reverse diseases of aging."

    Lynne Sullivan brings more than 20 years of experience working in the pharma and biotech industry. Ms. Sullivan worked at Biogen for over 10 years, serving as senior vice president of finance with global responsibility for corporate finance, financial planning and analysis and corporate tax. Ms. Sullivan is a member of the board of directors of four publicly traded biopharmaceutical companies, Inozyme Pharma, Solid Biosciences, resTORbio and BiomX, and most recently served as the chief financial officer for Compass Therapeutics. She received an M.S. in taxation from Bentley University and a B.S.B.A. from Suffolk University. Ms. Sullivan was a Certified Public Accountant for over 20 years.

    About UNITY

    UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's initial focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related diseases, such as osteoarthritis, eye diseases, neurological diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.

    Forward-Looking Statements

    This press release contains forward-looking statements including statements related to the potential for UNITY to develop therapeutics to extend healthspan. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process and risks relating to UNITY's understanding of senescence biology. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITY's most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the Securities and Exchange Commission on July 31, 2020, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

    This press release concerns drug candidates that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. They are currently limited by Federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated. All forward-looking statements are qualified in their entirety by this cautionary statement.

     

    Investors 
    Endurance Advisors
    Mike Zanoni
      
    
    Media 
    Canale Communications
    Jason Spark
    

    Primary Logo

    View Full Article Hide Full Article
    • UBX0101 failed to meet 12-week primary endpoint
    • Guidance for UNITY's Bcl-xL inhibitor UBX1325 in retinal disease remains unchanged
    • UNITY to focus senescence programs on ophthalmologic and neurologic diseases in near-term
    • UNITY to hold investor and analyst conference call today, Monday, August 17, 2020, at 8:00 a.m. EDT

    SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced the 12-week results from the Phase 2 study of UBX0101, a p53/MDM2 interaction inhibitor, in patients with moderate-to-severe painful osteoarthritis (OA) of the knee.  There was no statistically…

    • UBX0101 failed to meet 12-week primary endpoint
    • Guidance for UNITY's Bcl-xL inhibitor UBX1325 in retinal disease remains unchanged
    • UNITY to focus senescence programs on ophthalmologic and neurologic diseases in near-term
    • UNITY to hold investor and analyst conference call today, Monday, August 17, 2020, at 8:00 a.m. EDT

    SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced the 12-week results from the Phase 2 study of UBX0101, a p53/MDM2 interaction inhibitor, in patients with moderate-to-severe painful osteoarthritis (OA) of the knee.  There was no statistically significant difference between any arm of UBX0101 and placebo at the 12-week endpoint for change from baseline in WOMAC-A, an established measurement of pain in OA. Given these results, UNITY does not anticipate progressing UBX0101 into pivotal studies and will narrow the company's near-term focus to its ongoing ophthalmologic and neurologic disease programs.

    "Osteoarthritis of the knee is a debilitating disease for many individuals," said Jamie Dananberg, M.D., chief medical officer of UNITY. "While we are disappointed in the outcome of the 12-week results of the Phase 2 study of UBX0101, I would like to acknowledge our team's hard work and commitment to executing a robust study that has provided clear results."

    The company expects to complete collection of the Phase 2 24-week data, as well as that from the ongoing Phase 1b high-dose, repeat-dose study in the second half of 2020. The full results from the Phase 2 and Phase 1b studies will be presented at a future medical meeting.   

    Phase 2 12-week Data

    In the Phase 2 double-blind, placebo-controlled study, 183 patients with moderate to severe painful OA of the knee were randomized to receive placebo, 0.5 mg, 2.0 mg or 4.0 mg of UBX0101 via a single intra-articular injection. The analysis results for the primary endpoint are shown in the table below.

     Primary Endpoint: Least Square Means Change from Baseline in WOMAC-A (0-4 scale) at Week 12
    TreatmentWK 12 CFBLPbo-Adjusted CFBL Wk 12P-Value*
    Placebo (N = 46)-1.017N/AN/A
    UBX0101 0.5 mg (N = 45)-0.9240.0930.5222
    UBX0101 2.0 mg (N = 46)-1.052-0.0350.8069
    UBX0101 4.0 mg (N = 46)-1.019-0.0020.9870

    * P-Value is obtained from MMRM testing CFBL against Placebo

    UBX0101 was well-tolerated at all dose levels and adverse events (AEs) were consistent with previously reported data. There were no treatment-related serious AEs and only one patient discontinued because of an AE (for an unrelated cardiovascular event). The most common treatment emergent AE was procedural pain in the study knee (n = 10/183 (5.5%)).

    "Developing novel treatments that selectively eliminate or modulate senescent cells is at the heart of what we do, and we have generated valuable data that will enable us to learn from this study and inform future studies in diseases of aging," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "While these are not the results we had hoped for, the evidence that senescent cells contribute to diseases of aging remains compelling, and we are excited to advance UBX1325 for retinal diseases, which inhibits Bcl-xL, a distinct senolytic target. Diabetic macular edema and diabetic retinopathy are attractive not only because of the strength of underlying biology, but also because of the sensitive, quantitative, and objective clinical assessments available. The burden of senescent cells in various diseases of aging is increasingly evident, which together with our research gives us great conviction in our science and the future of our pipeline."

    Additional information about the study can be found on www.clinicaltrials.gov (NCT04129944).

    Financial Outlook

    Based on current operating plans, UNITY believes that current cash, cash equivalents and investments are sufficient to fund operations well into 2022.

    Conference Call Information

    UNITY will host a conference call and webcast for investors on Monday, August 17, 2020 at 8:00 a.m. EDT to discuss the UBX0101 clinical data. The live webcast can be accessed in the "Investors and Media" section of our website, www.unitybiotechnology.com, under "Events & Presentations" or by clicking here. You may also listen to the call by dialing 1-877-235-8637 within the U.S. or 1-704-815-6400 outside the U.S. and providing conference ID 6688134. A replay will be available two hours after the completion of the call and can be accessed in the "Investors & Media" section of our website, www.unitybiotechnology.com, under "Events and Presentations."

    About UNITY

    UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's initial focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related diseases, such as osteoarthritis, eye diseases, neurological diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.

    Forward-Looking Statements

    This press release contains forward-looking statements including statements related to the expected timing of date from the 24-week endpoints from UNITY's Phase 2 clinical study and Phase 1b high-dose, repeat-dose clinical study of UBX0101, statements regarding UNITY's understanding of cellular senescence and the role it plays in osteoarthritis and retinal diseases, the potential for UNITY to develop therapeutics to extend healthspan, including UBX1325 for retinal disease, expectations regarding the results of UNITY's clinical studies and UNITY's expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITY's most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the Securities and Exchange Commission on July 31, 2020, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

    Investors  

    Endurance Advisors

    Mike Zanoni

    Media 

    Canale Communications

    Jason Spark

    Primary Logo

    View Full Article Hide Full Article
  4. SAN FRANCISCO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it has entered into a $80 million debt facility with Hercules Capital (NYSE:HTGC).

    "With this financing UNITY has strengthened its balance sheet and we now have additional financial flexibility around the development of our lead senolytic clinical candidates, UBX0101 and UBX1325," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "We are excited to be working with the Hercules team who has significant experience supporting innovative life science companies."

    UNITY drew down $25 million from the debt…

    SAN FRANCISCO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it has entered into a $80 million debt facility with Hercules Capital (NYSE:HTGC).

    "With this financing UNITY has strengthened its balance sheet and we now have additional financial flexibility around the development of our lead senolytic clinical candidates, UBX0101 and UBX1325," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "We are excited to be working with the Hercules team who has significant experience supporting innovative life science companies."

    UNITY drew down $25 million from the debt facility at closing. An additional $30 million will be available for drawdown subject to the achievement of future milestones. The remaining $25 million will be available for drawdown subject to approval by Hercules.

               

    "This structured financing represents a significant commitment from Hercules and it is consistent with our goal of supporting innovative life sciences companies with strong institutional support through all stages of development," said Cristy Barnes, Managing Director at Hercules. "Hercules is pleased to enter into this financing partnership with Unity as it continues to advance its unique pipeline targeting age-related diseases," added Himani Bhalla, Principal at the Life Sciences lending group at Hercules.

    Further information with respect to the debt financing agreement with Hercules will be contained in a Current Report to be filed on Form 8-K by UNITY with the Securities and Exchange Commission.

    About UNITY

    UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's initial focus is on creating senolytic medicines that target senescent cells to alter the course of diseases of aging, such as osteoarthritis, eye diseases, neurological diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.

    Investors 
    Endurance Advisors
    Mike Zanoni
      
    
    Media 
    Canale Communications
    Jason Spark
    

    Primary Logo

    View Full Article Hide Full Article
View All Unity Biotechnology Inc. News